Etravirine

• Description :

  Etravirine (R165335; TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV.

• Product Name Alternative :

  R165335; TMC125

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H413

• Target :

  HIV; Reverse Transcriptase

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/etravirine.html

• Purity :

  99.07

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  N#CC1=CC(C)=C(C(C)=C1)OC2=NC(NC3=CC=C(C=C3)C#N)=NC(N)=C2Br

• Molecular Formula :

  C20H15BrN6O

• Molecular Weight :

  435.28

• Precautions :

  H302, H413

• References & Citations :

  [1]Andries, K., et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2004. 48 (12) : p. 468|[2]Lazzarin, A., et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 2007. 370 (9581) : p. 39-48.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  HIV-1; HIV-2

• CAS Number :

  [269055-15-4]